LEWIS JOEL 4

What Happened

• Joel Lewis, President & CEO and a director of Galectin Therapeutics, received two equity awards on Jan 16, 2026: 84,000 option awards and 120,000 restricted stock units (RSUs). Both awards are reported as derivative grants with an acquisition price of $0.00 (typical for compensation grants). Combined total awarded: 204,000 units.

Key Details

• Transaction date: January 16, 2026; Form 4 filed January 21, 2026.
• Award types and counts: 84,000 options (derivative) and 120,000 RSUs (derivative); acquisition price reported $0.00.
• Plan: Issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan (footnote F1).
• Vesting: Options vest 25% on each of June 30, 2026; Dec 31, 2026; June 30, 2027; and Dec 31, 2027 (F2). RSUs vest 100% on the earlier of Dec 31, 2026 or signing of a partnership agreement (F3) and convert to common stock 1-for-1 when vested (F4).
• Shares owned after transaction: Not disclosed in the filing.
• Timeliness: The Form 4 was filed Jan 21 for a Jan 16 transaction — beyond the usual two business-day filing window for insiders, so the filing appears late.

Context

• These awards are compensation grants (not open-market purchases) and represent a future right to common stock rather than immediate cash or freely tradable shares. Options require vesting per the schedule before they can be exercised; vested RSUs convert one-for-one to common stock. Such grants are common executive compensation and do not, by themselves, indicate an insider buying or selling stock.